What does Tirzepatide do? Benefits and evidence

Tirzepatide is a weekly injection approved for type 2 diabetes, weight management and sleep apnea in defined groups. Mounjaro also has a US cardiovascular-risk indication for eligible adults. Large trials support its effects on glucose and weight. Nausea, vomiting and diarrhea are common; dehydration, gallbladder problems and pancreatitis need attention. Online microdosing and stacking have much weaker evidence.

• Zepbound is approved for long-term weight management in adults with obesity, or overweight with a weight-related condition. (Drug label)
• Mounjaro is approved for type 2 diabetes from age 10, and Zepbound for moderate-to-severe sleep apnea in adults with obesity. (Drug label)
• In head-to-head trials, it lowered blood sugar more than semaglutide 1 mg and led to more weight loss than obesity-dose semaglutide. (Studied in a trial)
• In a large trial, fewer people with prediabetes went on to develop diabetes while on treatment. (Studied in a trial)

Uses in the sources

• Zepbound is approved for long-term weight management in adults with obesity, or overweight with a weight-related condition. (Drug label) (source)
• Mounjaro is approved for type 2 diabetes from age 10 and for major cardiovascular risk reduction in eligible adults. (Drug label) (source)
• Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity. (Drug label) (source)
• Studied for MASH with liver scarring, obesity-related HFpEF and type 1 diabetes with obesity; these are separate from the US labeled indications. (Studied in a trial) (source)
• People use very low doses for wellness or inflammation; a longevity benefit has not been established. (Reported by users) (source)